
Sign up to save your podcasts
Or


Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.
Continue this conversation on social!
The Lancet Infectious Diseases in conversation with... is part of the Lancet Group podcast offering.
Editorial team: editor-in-chief Ursula Hofer, deputy editor Marco De Ambrogi, and senior editors Syeda Saleha Hassan and Phoebe Hall
Podcast editing: Matteo Simonetti
Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.
Find the best science for better lives at lancet.com
By The Lancet GroupPrasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.
Continue this conversation on social!
The Lancet Infectious Diseases in conversation with... is part of the Lancet Group podcast offering.
Editorial team: editor-in-chief Ursula Hofer, deputy editor Marco De Ambrogi, and senior editors Syeda Saleha Hassan and Phoebe Hall
Podcast editing: Matteo Simonetti
Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.
Find the best science for better lives at lancet.com

9,194 Listeners

22 Listeners

0 Listeners

0 Listeners

3 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

91 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners